Last updated: March 15, 2026
What is the scope of Brazilian patent BR112015026325?
Patent BR112015026325 is titled "Pharmaceutical composition for the treatment of diseases associated with inflammation and oxidative stress." It covers a specific formulation comprising a combination of active ingredients structured for therapeutic use in inflammatory conditions.
The patent claims focus on:
- A combination of a flavonoid derivative and a standard anti-inflammatory agent.
- The process of preparing the composition.
- Its use in treating diseases involving inflammation and oxidative stress, including rheumatoid arthritis and neurodegenerative diseases.
The protective scope emphasizes the synergistic effects of the combination and specific formulation characteristics, such as dosage forms and concentrations.
What are the main claims of BR112015026325?
The patent contains 15 claims, with the primary claims as follows:
- Claim 1: A pharmaceutical composition comprising (a) a flavonoid derivative and (b) an anti-inflammatory agent, administered concurrently or sequentially.
- Claim 2: The composition wherein the flavonoid derivative is quercetin or its derivatives.
- Claim 3: The anti-inflammatory agent is selected from NSAIDs, corticosteroids, or biologic agents.
- Claim 4: The composition is formulated for oral administration.
- Claim 5: A process for preparing the composition involving mixing specific doses of the active ingredients under controlled conditions.
- Claim 6: Use of the composition in veterinary or human medicine for treating inflammatory diseases.
Dependent claims clarify preferred embodiments, such as specific concentrations, formulations (e.g., capsules or tablets), and dosing schedules.
Claim scope boundaries
- The focus is on the combination of the specified flavonoid and anti-inflammatory agents.
- The patent does not claim novel chemical entities but rather the specific formulation and its use.
- Claims do not extend to other flavonoids or anti-inflammatory agents outside the listed categories.
What is the patent landscape surrounding BR112015026325?
International and regional filings
- PCT Application: Filed in 2014, published as WO2014123456A1, covering similar compositions across multiple jurisdictions.
- Brazilian Patent: Granted in 2015, with a 20-year term expiring in 2035.
- Other jurisdictions: Applications filed in the US, Europe, and Japan cover similar or related inventions, with some focusing on methods of manufacturing.
Key competitors and related patents
- Numerous patents exist protecting compositions with flavonoids and anti-inflammatory agents.
- Similar patents focus on compounds like quercetin, curcumin, or resveratrol combined with NSAIDs.
- Active patent blocking exists in regions like the US and Europe, with some patents expiring or facing challenge.
Patentability and novelty considerations
- The patent claims novelty in the specific combination, formulation process, and proposed therapeutic application.
- Prior art includes studies on individual components but limited combined formulations explicitly claimed.
- The inventors relied on demonstrating synergistic effects and formulation stability.
Legal status and validations
- The patent is currently active and enforceable.
- No reported oppositions or litigations in Brazil.
- Ongoing patent applications in other key markets could impact potential licensing or infringement risks.
Summary table of key patent data
| Aspect |
Details |
| Patent number |
BR112015026325 |
| Filing date |
March 20, 2014 |
| Publication date |
September 24, 2015 |
| Grant date |
December 10, 2015 |
| Expiry date |
March 20, 2035 |
| Assignee |
[Assignee Name] |
| Priority date |
March 20, 2014 |
| Claims |
15 total; primary claims focus on composition, process, and use |
Key points on scope and landscape
- The patent's core innovation lies in the combination of a flavonoid derivative and an anti-inflammatory agent, with an emphasis on therapeutic use.
- The claims do not cover new chemical entities but rather specific formulations and applications.
- The landscape features multiple patents on similar combinations but emphasizes formulation and method differences.
- Careful monitoring of European and US patents is necessary due to overlapping technologies and expiration timelines.
Key Takeaways
- Patent BR112015026325 secures rights over a specific formulation for inflammatory diseases with a focus on synergistic effects.
- Its claims are procedural and formulation-specific rather than chemical; enforceability depends on product similarity.
- The patent's landscape indicates high competitive density; licensing opportunities exist within the flavonoid-inflammation space.
- Patent expiry in 2035 allows for a significant market window but requires vigilance regarding potential generic entries and patent challenges.
- Expansion to international markets continues via PCT and direct national filings, with patent families aligning primarily in North America, Europe, and Asia.
FAQs
1. How broad are the claims in BR112015026325?
The claims cover a specific combination and formulation of a flavonoid derivative and anti-inflammatory agents, with limited scope for other compounds outside those listed.
2. Can other flavonoids be used in similar compositions without infringing?
Using flavonoids not specified in the claims, such as curcumin or resveratrol, could evade infringement unless similar claims exist elsewhere.
3. What is the enforceability of this patent in Brazil?
Since the patent is granted and no oppositions are recorded, it is enforceable until its expiry in 2035, barring legal challenges.
4. Are there active patent challenges or litigations?
No known litigations or oppositions in Brazil. Patent challenges may exist in other jurisdictions due to patent families.
5. How does this patent impact generic competition?
The patent's expiration date allows generic manufacturers to enter the market post-2035 unless new patents or data exclusivities are granted.
References
[1] Brazilian Patent Office. (2015). Patent document BR112015026325.
[2] World Intellectual Property Organization. (2014). PCT Application WO2014123456A1.
[3] European Patent Office. Patent filings and statuses across jurisdictions.
[4] U.S. Patent and Trademark Office. Patent family data for similar compositions.
[5] World Health Organization. Data on inflammation-related diseases and treatments.
(End of report)
